EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structural and functional analysis of VYD222: A broadly neutralizing antibody against SARS-CoV-2 variants

Meng Yuan, Brandyn R. West, William B. Foreman, Colin Powers, Ziqi Feng, Ashley L. Taylor, Xinye Yu, Grace Wang, Laura Walker, Tyler N. Starr, Robert Allen, Ian A. Wilson

PLOS Pathogens · 20.11.2026 · 22 (11) · e1014613

DOI: 10.1371/journal.ppat.1014613 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 20.11.2026. Verfasst von Meng Yuan und 11 weiteren Autor:innen. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, Adagio.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extensive mutations in SARS-CoV-2 spike protein have rendered most therapeutic monoclonal antibodies (mAbs) ineffective. However, here we describe how VYD222 (pemivibart), a human mAb re-engineered from ADG20 (adintrevimab) exhibits substantially improved neutralization potency and breadth against SARS-CoV-2 variants despite substantial virus evolution. VYD222 received FDA Emergency Use Authorization for pre-exposure prophylaxis of COVID-19 in certain immunocompromised adults and adolescents. Here we show potent neutralization of this antibody against a broad range of emerging variants, including the recently dominant XFG. X-ray crystal structures of VYD222 in complex with the receptor-binding domains of prototype SARS-CoV-2 and Omicron BA.5 demonstrate the molecular basis of how VYD222 accommodates the mutations in SARS-CoV-2 variants that escape other previous FDA-approved antibodies. Notably, many of the mutations between ADG20 and VYD222 occur in the second shell outside the paratope contact residues. Deep mutational scanning indicates that SARS-CoV-2’s ability to escape VYD222 is constrained by structural compatibility and the need to maintain receptor binding. These findings provide crucial insights into the escape-resistant neutralization of VYD222 against a broad panel of clinically relevant SARS-CoV-2 variants and offer valuable guidance for risk assessment of emergent variants.

Förderung

  • National Institute of Allergy and Infectious Diseases
  • Bill and Melinda Gates Foundation
  • Adagio
  • Searle Scholars Program
  • Invivyd

Zitieren

APA

Yuan, M., West, B. R., Foreman, W. B., Powers, C., Feng, Z., Taylor, A. L., Yu, X., Wang, G., Walker, L., Starr, T. N., Allen, R., & Wilson, I. A. (2026). Structural and functional analysis of VYD222: A broadly neutralizing antibody against SARS-CoV-2 variants. PLOS Pathogens, 22(11), e1014613. https://doi.org/10.1371/journal.ppat.1014613

Vancouver

Yuan M, West BR, Foreman WB, Powers C, Feng Z, Taylor AL, et al. Structural and functional analysis of VYD222: A broadly neutralizing antibody against SARS-CoV-2 variants. PLOS Pathogens. 2026;22(11):e1014613. doi:10.1371/journal.ppat.1014613

BibTeX
@article{Yuan2026,
  author = {Yuan, Meng and West, Brandyn R. and Foreman, William B. and Powers, Colin and Feng, Ziqi and Taylor, Ashley L. and Yu, Xinye and Wang, Grace and Walker, Laura and Starr, Tyler N. and Allen, Robert and Wilson, Ian A.},
  title = {Structural and functional analysis of VYD222: A broadly neutralizing antibody against SARS-CoV-2 variants},
  journal = {PLOS Pathogens},
  year = {2026},
  volume = {22},
  number = {11},
  pages = {e1014613},
  doi = {10.1371/journal.ppat.1014613}
}
Kostenlos starten →